Willem Meindert De Vos

This inventor holds 19 USPTO granted patents and 21 published patent applications, plus 1 CIPO patent and 19 EPO patents, primarily in Microbiome Therapeutics. Top assignees: Wageningen University, Academisch Medisch Centrum, Caelus Pharmaceuticals B.v.. Active years: 2013-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Willem Meindert De Vos. Retrieved from https://idiyas.com/inventor/willem-meindert-de-vos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 19 (Patent Applications = 21)

% Patents Active = 94.7

CIPO Patents = 1

EPO Patents = 19 (Patent Applications = 26)

Average Co-Inventor Count = 2.3

ph-index = 4

Forward Citations = 57(Granted Patents)

Location History:

Amsterdam, NL (2022)
Ede, NL (2013 - 2023)

Company Filing History:

8 out of 40

Wageningen University

patents

5 out of 28

Academisch Medisch Centrum

patents

5 out of 5

Caelus Pharmaceuticals B.v.

patents

4. 4 out of 100

Universitè Catholique De Louvain

patents

5. 2 out of 2

Wageningen Universiteit

Wageningen Unlversiteit

patent

where one patent can have more than one assignee

Years Active: 2013-2026

Loading Chart...

Areas of Expertise:

Intestinal Microbiome

Diabetes Mellitus

Autoimmune Disease

Metabolic Disorders

Cas9 Nucleases

Bacterial Compositions

Immune Signalling

Gastrointestinal Diseases

Vitamin B12 Deficiency

Insulin Resistance

Polypeptide Use

Peptide Production

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12766168 - Fecal matter for treatment of cachexia (2026-10-20),

2. 12653848 - FECAL MATTER FOR PREVENTING OR TREATING INTESTINAL MICROBIOME ABERRATIONS IN CESAREAN SECTION-BORN INFANTS (2026-06-16),

3. 12648928 - INTERVENTION STRATEGY FOR PREVENTION OR TREATMENT OF DIABETES MELLITUS, AUTOIMMUNE DISEASE, INFLAMMATORY DISEASE OR CARDIOVASCULAR DISEASE (2026-06-09),

4. 12642821 - USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS (2026-06-02),

5. 11802277 - Thermostable Cas9 nucleases (2023-10-31),

6. 11534465 - Fecal matter for treatment of autoimmune diseases (2022-12-27),

7. 11466057 - Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status (2022-10-11),

8. 11452746 - Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases (2022-09-27),

9. 11426436 - Bacteria-comprising compositions and methods of using the same for treating and/or preventing gastrointestinal, metabolic and/or other diseases (2022-08-30),

10. 11202807 - Bacterial species (2021-12-21),

11. 10988509 - Method of culturing (2021-04-27),

12. 10857189 - Compositions and methods for preventing and/or treating vitamin B12 deficiency (2020-12-08),

13. 10806758 - Methods for culturing and preservingand treating disease and preparation thereof (2020-10-20),

14. 10738089 - Use of a polypeptide for effecting immune signalling and/or affecting intestinal barrier function and/or modulating metabolic status (2020-08-11),

15. 10736924 - Use of pasteurizedfor treating metabolic disorders (2020-08-11),

Title: Innovations by Willem Meindert De Vos: Pioneering Genetic Engineering and Autoimmune Disease Treatment

Introduction: Willem Meindert De Vos, located in Ede, NL, has a remarkable portfolio of 15 patents that reflect his innovative contributions to the fields of genetic engineering and medical treatment. His work not only advances scientific knowledge but also holds significant potential for real-world applications.

Latest Patents: Among his latest patents, the "Thermostable Cas9 nucleases" stands out as a significant advancement in genetic engineering. This invention focuses on nucleic acid editing and genome modification, providing isolated Cas proteins or polypeptide fragments capable of DNA cleavage at elevated temperatures ranging from 50°C to 100°C. The implications of this technology are vast, especially for the genetic manipulation of thermophilic organisms, particularly microorganisms. Another notable patent addresses the "Use of fecal matter for treatment of autoimmune diseases." This innovative approach utilizes autologous fecal matter to treat subjects with autoimmune diseases, with a focus on administering this treatment to the small intestine, specifically the duodenum. The patent encompasses various constituents of autologous feces, including bacteria, viruses, and metabolites.

Career Highlights: Willem has had a distinguished career, marked by his association with prominent research institutions such as Wageningen University and Caelus Pharmaceuticals B.V. His work at these organizations has contributed significantly to the advancement of science and technology in his field.

Collaborations: Collaboration plays a crucial role in innovation, and Willem has worked alongside notable coworkers like Clara Belzer and Max Nieuwdorp. Together, they have furthered their research initiatives, leveraging their collective expertise to create impactful innovations.

Conclusion: Willem Meindert De Vos exemplifies the spirit of innovation through his patents and collaborative efforts in genetic engineering and biomedical research. His contributions not only enhance scientific understanding but also pave the way for future advancements in treatment methodologies and genetic manipulation technologies.

Profile summary based on public USPTO records.